HC Wainwright reaffirmed their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX – Free Report) in a research note released on Thursday morning, Benzinga reports. They currently have a $20.00 target price on the stock.
Poseida Therapeutics Stock Down 3.5 %
Shares of NASDAQ PSTX opened at $2.45 on Thursday. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.48 and a current ratio of 2.48. Poseida Therapeutics has a 52-week low of $1.83 and a 52-week high of $4.27. The company’s 50 day moving average price is $2.85 and its 200-day moving average price is $2.88. The company has a market capitalization of $237.97 million, a P/E ratio of -2.06 and a beta of 0.51.
Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) last released its earnings results on Monday, August 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. Poseida Therapeutics had a negative net margin of 127.48% and a negative return on equity of 121.01%. The company had revenue of $25.97 million for the quarter, compared to the consensus estimate of $13.75 million. Equities analysts forecast that Poseida Therapeutics will post -1.57 earnings per share for the current year.
Institutional Trading of Poseida Therapeutics
Poseida Therapeutics Company Profile
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.
Recommended Stories
- Five stocks we like better than Poseida Therapeutics
- Energy and Oil Stocks Explained
- Is Spotify Stock Poised to Soar? Options Traders Think So
- What is the S&P/TSX Index?
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Using the MarketBeat Dividend Tax Calculator
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.